GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » EV-to-Revenue

Regencell Bioscience Holdings (Regencell Bioscience Holdings) EV-to-Revenue

: (As of Today)
View and export this data going back to 2021. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Regencell Bioscience Holdings's enterprise value is $56.83 Mil. Regencell Bioscience Holdings's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil. Therefore, Regencell Bioscience Holdings's EV-to-Revenue for today is .

The historical rank and industry rank for Regencell Bioscience Holdings's EV-to-Revenue or its related term are showing as below:

RGC's EV-to-Revenue is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.33
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-19), Regencell Bioscience Holdings's stock price is $5.55. Regencell Bioscience Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00. Therefore, Regencell Bioscience Holdings's PS Ratio for today is .


Regencell Bioscience Holdings EV-to-Revenue Historical Data

The historical data trend for Regencell Bioscience Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-Revenue
- - - - -

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regencell Bioscience Holdings EV-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's EV-to-Revenue falls into.



Regencell Bioscience Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Regencell Bioscience Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=56.826/0
=

Regencell Bioscience Holdings's current Enterprise Value is $56.83 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regencell Bioscience Holdings's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regencell Bioscience Holdings  (NAS:RGC) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Regencell Bioscience Holdings's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=5.55/0
=

Regencell Bioscience Holdings's share price for today is $5.55.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regencell Bioscience Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Traded in Other Exchanges
N/A
Address
29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Headlines

From GuruFocus